Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can salmon oil tame asthma? new study investigates

NCT ID NCT05137132

Disease control Sponsor: Hofseth Biocare ASA Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a salmon oil supplement called CARDIO® could help control asthma in adults. 70 participants took either the supplement or a placebo alongside their usual asthma medications. The goal was to see if the supplement reduced asthma attacks and improved breathing over 20 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

70 people

The number who actually took part.

Started

Apr 2022

Finished

Dec 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Asthma Global Initiative for Asthma (GINA) treatment grade 2-4 (only standard care of inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA), no additional treatment except as-needed short--acting beta2-agonist (SABA) * ACQ-5 score ≥0.75 * Diagnosed with asthma by medical doctor (general practitioner or pulmonary spesialist) * Eosinophils ≥ 150 µL * Speaks fluent Norwegian. * For female in fertile age, use of contraception or other indication for non-pregnancy. * Signed informed consent and expected cooperation of the participants for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations. Exclusion Criteria: * Treatment with oral corticosteroid \<1 month prior to baseline visit * Treatment with any biological medication, \<6 months prior to baseline visit * Oral/intravenous antibiotics \< 3 months prior to baseline visit * Consumption of fish oil (liquid, capsule, powder) as an oral supplement \< 1-month prior baseline visit * Known fish or shellfish allergy * Pregnancy and breast feeding * Participant in a confounding study * Inflammatory bowel disease (Chron, ulcerative colitis (UC), microscopic colitis), celiac disease, or any chronic disease that possibly affects intestinal absorption and morbidity * In case of severe cognitive impairment where the participants are not able to fulfill the study * Not willing to participate * Any reason why, in the opinion of the investigator, the participant cannot participate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Airway Obstruction asthma Dyspnea lung disorder pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma

Contacts and locations

Locations

  • Hofseth Biocare ASA

    Ålesund, More and Romsdal, 6003, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.